Toleranzia AB (TOL.ST)
SEK 0.4
(-2.68%)
SEK 0.4
(-2.68%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -7.39 Million SEK | 12.14% |
| 2022 | -8.42 Million SEK | -35.85% |
| 2021 | -6.19 Million SEK | -27.15% |
| 2020 | -4.87 Million SEK | 5.78% |
| 2019 | -7.52 Million SEK | 7.79% |
| 2018 | -5.61 Million SEK | -5.11% |
| 2017 | -5.33 Million SEK | -6.9% |
| 2016 | -4.99 Million SEK | -22.64% |
| 2015 | -4.07 Million SEK | -438.88% |
| 2014 | -714.49 Thousand SEK | -1110.46% |
| 2013 | 74.76 Thousand SEK | -5.61% |
| 2012 | 79.21 Thousand SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | -2.56 Million SEK | -60.09% |
| 2024 Q2 | -2.04 Million SEK | -112.9% |
| 2024 Q1 | -1.73 Million SEK | 60.27% |
| 2023 Q2 | -2.48 Million SEK | -28.25% |
| 2023 Q4 | -2.19 Million SEK | -113.81% |
| 2023 Q1 | -1.93 Million SEK | 4.86% |
| 2023 FY | - SEK | 10.4% |
| 2023 Q3 | -1.02 Million SEK | 58.6% |
| 2022 Q2 | -2.24 Million SEK | -8.59% |
| 2022 Q3 | -2.11 Million SEK | 5.9% |
| 2022 Q4 | -2.03 Million SEK | 3.69% |
| 2022 FY | - SEK | -35.85% |
| 2022 Q1 | -2.06 Million SEK | -20.68% |
| 2021 Q4 | -1.71 Million SEK | -12.77% |
| 2021 Q2 | -1.54 Million SEK | -9.02% |
| 2021 FY | - SEK | -27.15% |
| 2021 Q1 | -1.41 Million SEK | 12.46% |
| 2021 Q3 | -1.51 Million SEK | 1.74% |
| 2020 FY | - SEK | 5.78% |
| 2020 Q2 | -887.38 Thousand SEK | 32.17% |
| 2020 Q4 | -1.62 Million SEK | -53.07% |
| 2020 Q3 | -1.05 Million SEK | -19.29% |
| 2020 Q1 | -1.3 Million SEK | 59.72% |
| 2019 Q3 | -1.83 Million SEK | -37.33% |
| 2019 FY | - SEK | 7.79% |
| 2019 Q2 | -1.33 Million SEK | -18.28% |
| 2019 Q1 | -1.12 Million SEK | 25.14% |
| 2019 Q4 | -3.24 Million SEK | -76.96% |
| 2018 Q4 | -1.5 Million SEK | -29.16% |
| 2018 FY | - SEK | -5.11% |
| 2018 Q3 | -1.16 Million SEK | 22.51% |
| 2018 Q2 | -1.5 Million SEK | -5.75% |
| 2018 Q1 | -1.42 Million SEK | 8.38% |
| 2017 Q2 | -1.57 Million SEK | -20.17% |
| 2017 FY | - SEK | -6.9% |
| 2017 Q3 | -888.95 Thousand SEK | 43.68% |
| 2017 Q1 | -1.31 Million SEK | 26.86% |
| 2017 Q4 | -1.55 Million SEK | -75.1% |
| 2016 Q1 | -1.09 Million SEK | 58.83% |
| 2016 FY | - SEK | -22.64% |
| 2016 Q4 | -1.79 Million SEK | -80.41% |
| 2016 Q3 | -995.45 Thousand SEK | 10.13% |
| 2016 Q2 | -1.1 Million SEK | -1.26% |
| 2015 Q2 | -517.93 Thousand SEK | -82.57% |
| 2015 Q1 | -283.69 Thousand SEK | 2.58% |
| 2015 Q3 | -612.86 Thousand SEK | -18.33% |
| 2015 FY | - SEK | -438.88% |
| 2015 Q4 | -2.65 Million SEK | -333.48% |
| 2014 FY | - SEK | -1110.46% |
| 2014 Q4 | -291.21 Thousand SEK | 0.0% |
| 2013 FY | - SEK | -5.61% |
| 2012 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AcuCort AB | -13.69 Million SEK | 45.965% |
| AlzeCure Pharma AB (publ) | -37.86 Million SEK | 80.464% |
| BioGaia AB (publ) | 466.19 Million SEK | 101.587% |
| Enzymatica AB (publ) | -41.12 Million SEK | 82.01% |
| Enorama Pharma AB (publ) | -43.05 Million SEK | 82.817% |
| Gabather AB (publ) | 37 Thousand SEK | 20094.595% |
| Klaria Pharma Holding AB (publ.) | -14.77 Million SEK | 49.912% |
| Moberg Pharma AB (publ) | -26.95 Million SEK | 72.559% |
| Nanexa AB (publ) | -70.79 Million SEK | 89.55% |
| Newbury Pharmaceuticals AB (publ) | -12.34 Million SEK | 40.049% |
| ODI Pharma AB | 1.36 Million SEK | 641.041% |
| Orexo AB (publ) | -22 Million SEK | 66.373% |
| Probi AB (publ) | 115.61 Million SEK | 106.399% |
| Swedencare AB (publ) | 484 Million SEK | 101.529% |
| Swedish Orphan Biovitrum AB (publ) | 7.23 Billion SEK | 100.102% |
| Vivesto AB | -89.75 Million SEK | 91.758% |